Eisai Inc.

FDA Grants Priority Review for LEQEMBI Supplement Application

The FDA has granted priority review status for the supplemental application of LEQEMBI (lecanemab-IRMB) submitted by Eisai Inc.

FDA Grants Priority Review for LEQEMBI Supplement Application

The FDA has granted priority review status for the supplemental application of LEQEMBI (lecanemab-IRMB) submitted by Eisai Inc.

Merck initiates trial for pembrolizumab combinations in advanced ccRCC

Eisai Initiates Study on Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's Disease

Eisai Inc. is conducting a retrospective study to develop algorithms for identifying intracerebral hemorrhage and new-onset seizures in Alzheimer's patients using claims data linked to electronic health records.

Lenvatinib Evaluated for Invasive Thyroid Cancer Surgery Outcomes

A study is underway to assess the safety and efficacy of neoadjuvant lenvatinib in patients with invasive differentiated thyroid cancer.